Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
45 hedge funds and large institutions have $66.2M invested in Eiger BioPharmaceuticals, Inc. in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 6 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
6% less capital invested
Capital invested by funds: $70.4M → $66.2M (-$4.15M)
12% less funds holding
Funds holding: 51 → 45 (-6)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.13M |
| 2 |
HP
Hikari Power
Tokyo,
Japan
|
+$118K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$62K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$36.9K |
| 5 |
State Street
Boston,
Massachusetts
|
+$28.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.13M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$804K |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$362K |
| 4 |
Morgan Stanley
New York
|
-$76.1K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$65.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Group One Trading
Chicago,
Illinois
| – | -$344 | -1 | Closed |
|
EIGR Hedge Fund Activity: Q1 2017 in Review
45 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2017, worth a combined $66.2M — down 5.9% from $70.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EIGR and 5 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 11 added.
The largest buyer was BlackRock, adding an estimated $2.13M. The largest seller was Wellington Management Group, cutting an estimated $2.13M.
- 45 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2017, down from 51 in Q4 2016.
- Funds reported $66.2M of Eiger BioPharmaceuticals, Inc. stock for Q1 2017, down 5.9% quarter-over-quarter.
- 5 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2017 and 6 closed out, a net change of -1 holder.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2017 was BlackRock, an estimated $2.13M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2017 was Wellington Management Group, an estimated $2.13M sold.
Based on aggregated 13F filings for Q1 2017.